Compare RIGL & SMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RIGL | SMBC |
|---|---|---|
| Founded | 1996 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 698.0M |
| IPO Year | 2000 | 2011 |
| Metric | RIGL | SMBC |
|---|---|---|
| Price | $25.93 | $61.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $45.67 | ★ $67.75 |
| AVG Volume (30 Days) | ★ 365.0K | 46.5K |
| Earning Date | 03-03-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | ★ 1867.68 | 17.19 |
| EPS | ★ 19.48 | 3.00 |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $16.09 |
| Revenue Next Year | $12.23 | $5.69 |
| P/E Ratio | ★ $1.34 | $20.69 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $15.50 | $45.10 |
| 52 Week High | $52.24 | $66.56 |
| Indicator | RIGL | SMBC |
|---|---|---|
| Relative Strength Index (RSI) | 27.05 | 46.32 |
| Support Level | $18.14 | $59.32 |
| Resistance Level | $31.26 | $66.04 |
| Average True Range (ATR) | 1.39 | 1.79 |
| MACD | -0.19 | -0.09 |
| Stochastic Oscillator | 10.63 | 47.70 |
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.